


PHARMACEUTICAL 2022

Mirum Pharmaceuticals Inc. Rank 313 of 466







PHARMACEUTICAL 2022



Mirum Pharmaceuticals Inc. Rank 313 of 466

The relative strengths and weaknesses of Mirum Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirum Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Mirum Pharmaceuticals Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is 52%, being 26% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	166,592
Cost of Goods Sold	0
Intangible Assets	18,740
Liabilities, Current	42,596
Liabilities, Non-Current	1,920
Other Assets	108,338
Other Compr. Net Income	-118
Other Expenses	20,262
Other Liabilities	129,923
Other Net Income	107,784
Other Revenues	19,138
Property and Equipment	981
Research and Development	131,428
Selling, General and Administrative Expense	59,220

Output Variable	Value in 1000 USD
Assets	294,651
Liabilities	174,439
Expenses	210,910
Revenues	19,138
Stockholders Equity	120,212
Net Income	-83,988
Comprehensive Net Income	-84,047
Economic Capital Ratio	52%